Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

GIVAUDAN-ROURE SUBMITS PARSOL 1789 SAFETY DATA IN COMBINATION PRODUCTS

This article was originally published in The Tan Sheet

Executive Summary

GIVAUDAN-ROURE SUBMITS PARSOL 1789 SAFETY DATA IN COMBINATION PRODUCTS to FDA on Sept. 8. The submission includes five clinical studies and two guinea pig studies sponsored by Givaudan-Roure customers outside the U.S., as well as other data intended to support a Category I (safe and effective) listing of the broad- spectrum sunscreen. The data are intended to bolster the company's citizen petition seeking monograph status for Parsol 1789 (avobenzone).
Advertisement

Topics

Advertisement
UsernamePublicRestriction

Register

PS083256

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel